Opinion|Videos|October 11, 2024
Impact of IFM 2009 and DETERMINATION Studies
Key Takeaways
- Triplet therapy with VRd has improved progression-free survival in NDMM, altering induction treatment strategies.
- Clinicians now prioritize aggressive initial treatment to maximize PFS, influenced by VRd's efficacy.
Panelists discuss how the introduction of triplet therapy prior to transplant in studies like IFM 2009 and DETERMINATION shifted the clinician mindset toward more intensive induction regimens, leading to a focus on achieving deeper responses and longer progression-free survival as primary goals of therapy for newly diagnosed multiple myeloma patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- The pivotal IFM 2009 study found that VRd (bortezomib, lenalidomide, and dexamethasone) followed by transplantation significantly improved progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM). How did the introduction of triplet therapy prior to transplant change the clinician mindset when deciding induction treatment, and how has that impacted studies that came after?
- (Dr Adams) In DETERMINATION, VRd with upfront transplant was associated with longer PFS. How did this trial change the goals of primary therapy for patients with NDMM?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Addressing Drug Resistance in Lung Cancer
2
Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer
3
From Mutation to Medicine: Targeted Therapies in Lung Cancer
4
Tar-200 Plus Anti–PD-1 Therapy Shows Promising Neoadjuvant Activity in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
5
